Table 1 Patient characteristics
|  | All patients (N = 186) | Cases TIPN Gr 2–3 (N = 108) | Control TIPN Gr 0–1 (N = 78) |
|---|---|---|---|
Cancer Type | |||
 Breast ca. a | 135 | 67 | 68 |
 Ovarian ca. a | 51 | 41 | 10 |
Age (year) median (range) | 52 (25–81) | 56 (25–81) | 48 (27–73) |
Chemotherapy regimenb | |||
 AC or CEF f/b wPTX | 126 (68%) | 67 (62%) | 59 (77%) |
 AC or CEF f/b DTX | 5 (3%) | 0 | 5 (6%) |
 CPA + DTX | 4 (2%) | 0 | 4 (5%) |
 Dose dense TC | 39 (21%) | 34 (32%) | 5 (6%) |
 Tri TC | 12 (6%) | 7 (6%) | 5 (6%) |
Maximum grade of TIPNc | |||
 0 | 2 (1%) | 0 (0%) | 2 (3%) |
 1 | 76 (41%) | 0 (0%) | 76 (97%) |
 2 | 91 (49%) | 91 (84%) | 0 (0%) |
 3 | 17 (9%) | 17 (16%) | 0 (0%) |
Cumulative taxane dose (mg/m2) median (range) | |||
 PTX | 960 (560–1440) (N = 177) | 960 (560–1440) (N = 108) | 960 (688–1440) (N = 69) |
 DTX | 300 (270–400) (N = 9) | – | 300 (270–400) (N = 9) |
Time to develop TIPN (days) median (range) | 33 (7–79) | 28 (7–79) | 35 (7–77) |
Duration of TIPN (days) median (range) | 446 (0–1416) | 455 (70–1395) | 416 (0–1327) |
Grade of TIPN at 1 year after taxane | |||
 0 | 44 (24%) | 10 (9%) | 34 (44%) |
 1 | 74 (40%) | 38 (35%) | 36 (46%) |
 2 | 41 (22%) | 41 (38%) | 0 (0%) |
 3 | 2 (1%) | 2 (2%) | 0 (0%) |
 unknown | 25 (13%) | 17 (16%) | 8 (10%) |
Full dose administration of taxane | 132 (71%) | 63 (58%) | 69 (88%) |
Dose reduction or termination of taxane due to TIPN | 38 (20%) | 35 (32%) | 3 (4%) |
Dose reduction or termination due to other reasons | 16 (8%) | 10 (9%) | 6 (7%) |
SCN9A rs7607967 | |||
 GG | 24 (13%) | 15 (14%) | 9 (11%) |
 GA | 84 (45%) | 43 (40%) | 41 (53%) |
 AA | 78 (42%) | 50 (46%) | 28 (36%) |
SCN9A rs12994338 | |||
 TT | 13 (7%) | 9 (8%) | 4 (5%) |
 TC | 80 (43%) | 46 (43%) | 34 (44%) |
 CC | 93 (50%) | 53 (49%) | 40 (51%) |
SCN9A rs13017637 | |||
 TT | 3 (2%) | 1 (1%) | 2 (3%) |
 TC | 37 (20%) | 16 (15%) | 21 (27%) |
 CC | 146 (78%) | 91 (84%) | 55 (70%) |
SCN10A rs12632942 | |||
 GG | 44 (24%) | 28 (26%) | 16 (20%) |
 GA | 87 (47%) | 49 (45%) | 38 (49%) |
 AA | 55 (29%) | 31 (29%) | 24 (31%) |
SCN10A rs6795970 | |||
 AA | 4 (2%) | 3 (3%) | 1 (1%) |
 AG | 47 (25%) | 25 (23%) | 22 (28%) |
 GG | 135 (73%) | 80 (74%) | 55 (71%) |